STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
| Publication | Article in Future Oncology, published March 2023 |
|---|---|
| Authors | Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz,...[ show more ] |
This is the public page for a publication record in Dimensions, a free research insights platform that brings together information about funding, scholarly outputs, policy, patents and grants.
Loading metrics…